0108 Caplan QnA
BioCentury & Getty Images

Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

Bioethicist Arthur Caplan on how the post-pandemic world will see changes from patient consent to DSMBs to data dissemination

Bioethicist Arthur Caplan on how the post-pandemic world will see changes from patient consent to DSMBs to scientific publishing.

Jan 8, 2021 | 11:02 PM GMT

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan. The botched rollout of vaccines has lessons too.

In an interview with BioCentury, Caplan, head of the division of medical ethics at New York University School of Medicine, said the lagging distribution of vaccines in the U.S. and the U.K., in contrast to the much-lauded program in Israel, demonstrates the value of an integrated healthcare system and the importance of coupling that with a coordinated government strategy. 

As of Jan. 6, Israel had administered 18.4 doses per 100 people in the population, compared with 1.79 for the U.S. and 1.91 for the U.K., according to data from the University of Oxford. 

The poor rollouts have brought to the fore discussions about deviating from the authorized regimen to stretch supplies and immunize more people. Caplan disagrees with FDA’s stance to resist this, and argues desperate times call for desperate measures.

He also thinks that the process

Read the full 2684 word article

How to gain access

Continue reading with a
two-week free trial.